Cancer gene therapy market Size 2013-2017 | Forecast 2018-2024

22/mag/2018 09:11:45 sravan Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Cancer gene therapy market Size 2013-2017 | Forecast 2018-2024

 

Cancer gene therapy is a process that treats cancers by inserting therapeutic DNA into the patient. Cancer gene therapy is gaining popularity as a result of its success rate in preclinical and clinical trial stages. The most common technique for cancer gene therapy involves replacing a mutated gene that is causing cancer with a healthy copy of the gene. A new technique that is being introduced to cancer gene therapy market involves insertion of new genes into the body that would help to fight against tumor cells.

 

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. Various factors, such as the increase in the prevalence of cancer, rising government initiatives, increase in funding from various government and non-government organizations, ethical acceptance of gene therapy for treatment of diseases and growing popularity of DNA vaccines is driving the global cancer gene therapy market. However, less awareness and high cost involved in treatment, lack of reimbursement policies for advanced gene therapy methods are restraining the growth of the global market for cancer gene therapy.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-cancer-gene-therapy-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

The global cancer gene therapy market is divided into the following categories:

1.      Type

·         Gene Induced Immunotherapy

o    Tumour Antigen Gene Delivery

o    Cytokine Gene Delivery

·         Oncolytic Virotherapy

o    Adenoviruses

o    Adeno Associated Virus

o    Lentiviruses

o    Alpha Virus

o    Retrovirus

o    Herpes Simplex Virus

o    Vaccinia virus

o    Simian Virus

·         Gene Transfer/ Gene Replacement

·         Electroporation

·         Magnetofection

·         Naked / Plasmid Vectors

·         Gene Gun

·         Sonoporation

2.     Therapy

·         Retroviral Therapy

·         Adenoviral Therapy

3.     End-users

Hospitals, Oncology institutes, Biotechnological companies and Clinical Research Labs.

 

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-cancer-gene-therapy-market/#ulp-c654SbFYO64MsOhu

 

And lastly, on the basis of geographical regions, the cancer gene therapy is divided into North America, Europe, Latin America, Asia- Pacific and the Middle East and Africa. North America leads the global cancer gene therapy market owing to the large pool of aging population and advancements in technology high investments in R & D activities along with the government support will boost industry demand. The U.K. market is anticipated to grow rapidly over the forecast period due to the rising occurrence of cancer along with the increase in acceptance of gene technology. Asia-Pacific is expected to witness high growth in cancer gene therapy market, due to increase in government initiatives, rising economy, and improvement in healthcare infrastructure in the region. Some of the key driving forces for cancer gene therapy market in emerging countries are increasing R&D investment, a large pool of patients and rising government funding. Some of the major companies operating in the global cancer gene therapy market are Urigen Pharmaceuticals Inc. (U.S), GenVec.Inc (U.S), Oxford BioMedica (U.K), Vical (U.S), ANI Pharmaceuticals, Inc. (U.S), and Genzyme Corporation (U.S). Novartis AG (Switzerland), and Cell Medica (U.K.). In 2017, Novartis received USFDA Oncologic Drugs Advisory Committee (ODAC) recommended approval of CTL019, an investigational chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of relapsed or refractory pediatric and young adult patients with B-cell acute lymphoblastic leukemia. And in same year, Cell Medica acquired the Catapult Therapy TCR Limited, a subsidiary of Cell and Gene Therapy Catapult (CGT Catapult), and the initiation of a collaboration to establish cell therapy manufacturing for Cell Medica at CGT Catapult’s GMP manufacturing facility in Stevenage, UK. While back in 2013, BioSante Pharmaceuticals, Inc. completed the merger of its wholly-owned subsidiary with and into ANIP Acquisition Company, ANI Pharmaceuticals, Inc.

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/global-cancer-gene-therapy-market/#ulp-14mlyhjMGhVjZqa3

 

 

Global cancer gene therapy market is highly fragmented with small biotech firms holding a chunk of the overall industry share. Major industry participants adopting various strategies to retaining their market positions such as the development of advanced technologies, maintaining a strong intellectual property, strategic collaborations, and joint ventures adopted by in the global cancer gene therapy. As per WHO, cancer incidence is projected to rise by 50% to reach 15million by the end of this decade. This alarming increase in the number of patients and side effects associated with various chemotherapy drugs entails to a potential treatment approach addressing the growing global burden of the cancers. Small biotech firms dominate the global cancer gene therapy market than the bigger players. The players are constantly engaged in R&D in order to develop novel methods to treat various life-threatening diseases. Increased in the adoption of emerging genomic technologies such as Next Generation Sequencing (NGS) and high-density microarray coupled with favorable government initiatives will fuel global cancer gene therapy market. For instance, CDC supports nationwide screening programs for control of breast, cervical and colorectal cancer among low-income women with little or no health insurance.

 

Get access to full summary @

https://www.precisionbusinessinsights.com/market-reports/global-cancer-gene-therapy-market

 

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US):+1-866-598-1553

Website @https://www.precisionbusinessinsights.com

 

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl